

Cleaved Kininogen-1 HC (Lys380) Rabbit pAb

CatalogNo: YC0096

Key Features

Host Species

- Rabbit

Reactivity

- Human, Mouse, Rat

Applications

- WB, ELISA

MW

- 41kD (Observed)

Isotype

- IgG

Recommended Dilution Ratios

WB 1:500-1:2000

ELISA 1:10000

Not yet tested in other applications.

Storage

Storage*

-15°C to -25°C/1 year (Do not lower than -25°C)

Formulation

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Basic Information

Clonality

Polyclonal

Immunogen Information

Immunogen

Synthesized peptide derived from Cleaved-Kininogen-1 HC (K380) . at AA range: 300-380

Specificity

Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody detects endogenous levels of fragment of activated Kininogen-1 HC protein resulting from cleavage adjacent to K380.

Target Information

Gene name KNG1 BDK KNG

Protein Name Kininogen-1


Organism	Gene ID	UniProt ID
Human	3827 ;	P01042 ;
Mouse		O08677 ;

Cellular Localization Secreted, extracellular space.

Tissue specificity Secreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.

Function Disease:Defects in KNG1 are the cause of high molecular weight kininogen deficiency (HMK deficiency) [MIM:228960]. HMK deficiency is an autosomal recessive coagulation defect. Patients with HMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.,Function:(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.,online information:High molecular weight kininogen entry,polymorphism:The T-kinin peptide is missing residues 378 to 380, probably as a result of a naturally occurring variant. The complete sequence of the T-kinin peptide is therefore ISRPPGFSPFR. This peptide is associated with malignant tumors but not with benign ones.,PTM:Bradykinin is released from kininogen by plasma kallikrein.,PTM:Hydroxylation of Pro-383 occurs prior to the release of bradykinin.,similarity:Contains 3 cystatin domains.,tissue specificity:Plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.,

Validation Data



Western Blot analysis of 293 cells using Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody

| Contact information

Orders: order@immunoway.com
Support: tech@immunoway.com
Telephone: 877-594-3616 (Toll Free), 408-747-0185
Website: <http://www.immunoway.com>
Address: 2200 Ringwood Ave San Jose, CA 95131 USA



Please scan the QR code
to access additional
product information:

**Cleaved
Kininogen-1 HC
(Lys380) Rabbit pAb**

For Research Use Only. Not for Use in Diagnostic Procedures.

[Antibody](#) | [ELISA Kits](#) | [Protein](#) | [Reagents](#)